Details

Autor(en) / Beteiligte

• Addad, Faouzi
• Chakroun, Tahar
• Elalamy, Ismail
• Abderazek, Fatma
• Chouchene, Saoussen
• Dridi, Zohra
• Gerotziafas, Gregoris T.
• Hatmi, Mohamed
• Hassine, Mohsen
• Gamra, Habib

Titel

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes

Ist Teil von

• International journal of hematology, 2010-09, Vol.92 (2), p.296-301

Ort / Verlag

Japan: Springer Japan

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients. Twenty-five CAD diabetic patients were included. Initially, all patients received aspirin 100 mg/day for 10 days. At day 10, aspirin antiplatelet effect was determined by measuring the collagen/epinephrine closure time (CT) 2 h after the last aspirin dosage and the next morning at 8 a.m.. The aspirin regimen was modified to 100 mg twice daily for patients showing a non-optimal platelet-inhibitory effect (CT < 298 s at 8 a.m.). Persistent high platelet reactivity (HPR) was defined by a CT < 160 s. During the 100 mg/day aspirin regimen, the prevalence of HPR at 8 a.m. was 48%, and only 7 patients (28%) had showed an optimal platelet-inhibitory effect. Bridging to the twice-daily regimen, the HPR was significantly reduced ( p  = 0.025), and the optimal platelet-inhibitory effect was reached for 3 other patients. Our results showed that 100 mg aspirin twice-daily dosing rather than a once-daily dose significantly improves the aspirin effect on platelet of CAD diabetic patients. However, large prospective studies were needed to confirm whether this strategy will be clinically relevant and safe.